Cancer Plasma Cell Myeloma Recurrent clinical trials

Explore recruiting cancer plasma cell myeloma recurrent clinical trials.

Recruiting cancer plasma cell myeloma recurrent studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cancer Plasma Cell Myeloma Recurrent trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM)

France, Italy, Germany, Poland, Czechia, Hungary +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cancer Plasma Cell Myeloma Recurrent trials by city

Cancer Plasma Cell Myeloma Recurrent clinical trials

Recruiting cancer plasma cell myeloma recurrent studies right now

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

CAR-T in Relapsed/Refractory Multiple Myeloma

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Also recruiting in Europe

A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM)

Cancer Plasma Cell Myeloma Recurrent trials by city

Other conditions